Krystal Biotech Inc.

5 days ago · defenseworld.net

Corient Private Wealth LP boosted its position in Krystal Biotech, Inc. (NASDAQ: KRYS) by 767.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,558 shares of the company's stock after purchasing an additional 27,035 shares during the

19 days ago · zacks.com

KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.

20 days ago · zacks.com

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

2 months ago · zacks.com

KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.

2 months ago · seekingalpha.com

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

2 months ago · marketbeat.com

Krystal Biotech NASDAQ: KRYS reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for patients with dystrophic epidermolysis bullosa, or DEB, in the United States and overseas.

2 months ago · zacks.com

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.79 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $1.29 per share a year ago.

2 months ago · globenewswire.com

$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance sheet, ending the quarter with $1.1 billion in cash and investments PITTSBURGH, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company” or “Krystal”) (NASDAQ: KRYS) today reported financial results for the second quarter ended June 30, 2026 and provided a business update. “Our second quarter reflects the strength of the Krystal model: a global commercial product that continues to perform, a strong balance sheet, and a pipeline now moving toward multiple registrational readouts,” said Krish S.

2 months ago · seekingalpha.com

Krystal Biotech (KRYS) earns a STRONG BUY rating, driven by its fortress-like balance sheet, exceptional margins, and rapid Vyjuvek commercial success. KRYS's international Vyjuvek launches in Europe and Japan are accelerating topline growth, with further expansion into Italy, Spain, and the UK expected to boost revenues. KRYS's pipeline, leveraging its proprietary HSV-1 platform, spans respiratory, ophthalmology, oncology, and aesthetics, reducing future reliance on Vyjuvek.

2 months ago · seekingalpha.com

Krystal Biotech remains a Buy as VYJUVEK drives profitability and its HSV-1 platform underpins a robust pipeline. Q1 results highlight operating leverage: $116.4M VYJUVEK revenue, $56M net income, and self-funded R&D with a $1B cash position. Upcoming catalysts include registrational data for KB803 and KB801, with KB801 positioned as a potential blockbuster in rare ophthalmology.